secwatch.observer — SEC 8-K summary
======================================

Issuer:     Damora Therapeutics, Inc. (DMRA)
CIK:        0001800315
Form:       8-K
Filed at:   2022-01-27T23:59:59+00:00
Accession:  0001564590-22-002577
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galecto reports safety and efficacy of GB0139 in COVID-19; 21% mortality reduction in high-risk subgroup
--------------------------------------------------------------------------------

- Study met primary safety endpoint: no treatment-related adverse events in 20 GB0139 patients.
- Target engagement confirmed: statistically significant reduction in serum galectin-3 (p<0.01).
- GB0139-treated patients had significantly greater rate of decline in oxygen requirement vs standard of care.
- In high-risk subgroup, 21% mortality reduction observed; company plans co-development for COVID-19.
- GALACTIC-1 IPF trial: amendment to reduce target patients, topline expected mid-2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800315/000156459022002577/0001564590-22-002577-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800315/000156459022002577/glto-8k_20220127.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-002577

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer